Mammoth Biosciences | Evaluate

January 10, 2022

JP Morgan 2022 – day one sees healthy deal flow from biopharma

But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.

January 10, 2022

JP Morgan 2022 – Beam and Mammoth hook big pharma partners

Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.

October 26, 2021

Vertex goes small with Mammoth deal

Vertex strikes yet another gene editing deal, this time with the “ultra-small” Crispr specialist Mammoth.